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Background: The present study was designed to prepare and ﬁnd the optimum active preparation or
fraction from Korea Red Ginseng inhibiting matrix metalloproteinase-13 (MMP-13) expression, because
MMP-13 is a pivotal enzyme to degrade the collagen matrix of the joint cartilage.
Methods: From total red ginseng ethanol extract, n-BuOH fraction (total ginsenoside-enriched fraction),
ginsenoside diol-type-enriched fraction (GDF), and ginsenoside triol-type-enriched fraction (GTF) were
prepared, and ginsenoside diol type-/F4-enriched fraction (GDF/F4) was obtained from Panax ginseng leaf
extract.
Results: The n-BuOH fraction, GDF, and GDF/F4 clearly inhibited MMP-13 expression compared to
interleukin-1b-treated SW1353 cells (human chondrosarcoma), whereas the total extract and ginseno-
side diol-type-enriched fraction did not. In particular, GDF/F4, the most effective inhibitor, blocked the
activation of p38 mitogen-activated protein kinase (p38 MAPK), c-Jun-activated protein kinase (JNK), and
signal transducer and activator of transcription-1/2 (STAT-1/2) among the signal transcription pathways
involved. Further, GDF/F4 also inhibited the glycosaminoglycan release from interleukin-1a-treated
rabbit cartilage culture (30.6% inhibition at 30 mg/mL).
Conclusion: Some preparations from Korean Red Ginseng and ginseng leaves, particularly GDF/F4, may
possess the protective activity against cartilage degradation in joint disorders, and may have potential as
new therapeutic agents.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
The extracellular matrix (ECM) provides tension and strength in
human articular cartilage. ECM consists of mainly collageneous
materials and aggrecans [1], which are maintained under the
control of a normal turnover process between new ECM synthesis
by residing chondrocytes and breakdown by matrix metal-
loproteinases (MMPs) and aggrecanases. In certain pathological
conditions, such as osteoarthritis, however, some MMPs are highly
induced and degrade ECM. Among the MMPs, MMP-13 is the most
important collagenase to degrade and destabilize ECM in human
articular cartilages [2e4]. In this regard, it is thought that MMP-13
inhibitor(s) and/or downregulator(s) may play a beneﬁcial thera-
peutic role of chondroprotection.won National University, Hyoja-2
erms of the Creative Commons At
ribution, and reproduction in any
e Korean Society of Ginseng, PublKorean Red Ginseng (steamed white ginseng, Panax ginseng
Meyer) is famous for possessing various biological effects, including
enhancing vital energy, enhancing immune capacity, and inhibition
of cancer cell growth. Its major constituents are various ginseno-
sides that have been reported to exhibit numerous pharmacological
activities, including vitality enhancement, immune modulation,
and anticancer activity [5e7]. However, few investigations or few
clinical studies of ginsenosides on cartilage degradation disorders
have been reported.
Among the ginsenosides fromKorean Red Ginseng, some are not
present in white ginseng products [8,9]. Examples are ginsenoside
Rg3, Rg5, Rk1, and F4 that are only detected in red ginseng extract.
Previously, one ginsenoside, Rg3, was found to inhibit MMP-13
expression in human osteoarthritic chondrocytes [10]. We havedong, Chunchon 200-701, Korea.
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Fig. 1. The chemical structures of ginsenosides and representative high-performance liquid chromatograms (HPLC) of the preparations from Korean Red Ginseng and ginseng leaves
used in this study. (A) Chemical structures of ginsenosides. (B) HPLC of Korean Red Ginseng total extract. (C) HPLC of n-butanol fraction. The retention time and % of the area of each
ginsenoside were: 11.43 min and 4.19% for Rg1; 11.90 min and 6.47% for Re; 20.27 min and 2.33% for Rf; 24.67 min and 7.73% for Rh1; 28.93 min and 30.89% for Rb1; 30.30 min and
16.24% for Rb2; 31.63 min and 7.89% for Rc; 34.43 min and 3.37% for Rd;46.40 min and 7.07% for Rg3(S); 47.93 min and 3.22% for Rg3(R); 54.30 min and 1.52% for Rk1; and 54.90 min
and 2.47% for Rg5. (D) HPLC of ginsenoside diol-type-enriched fraction. (E) HPLC of ginsenoside diol-type-enriched fraction (GDF). (F) HPLC of GDF/F4. Note: Compared to GDF, GDF/
F4 contains more hydrophobic ginsenosides such as F4, Rg3, and Rg5. ELSD stands for evaporative light scattering detection.
J.H. Lee et al / MMP-13 downregulation of KRG 55recently found that certain ginsenosides including Rc, Rd, Rf, F4,
Rg1, and Rg3 inhibit MMP-13 induction from human chondrocytes,
and some also block glycosaminoglycan (GAG) release from inter-
leukin (IL)-1a-treated cartilage culture to some degree [11]. Theseprevious ﬁndings strongly suggest that the Korean Red Ginseng
products and/or some ginsenoside-enriched preparations may
possess a signiﬁcant inhibitory activity of MMP-13 expression
and thereby block cartilage degradation. Thus, several ginseng
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Fig. 1. (continued).
J Ginseng Res 2015;39:54e6056preparations have been designed and prepared in the present
study. They were examined for MMP-13 downregulatory effect and
cartilage protection to ﬁnd a potential for a new chondroprotective
agent. This is the ﬁrst report of the preparations from Korean Red
Ginseng and ginseng leaves to show MMP-13 downregulating
properties.
2. Materials and methods
2.1. Chemicals
Human IL-1a, IL-1b, dexamethasone, diclofenac, 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and
anti-MMP-13 antibody were purchased from SigmaeAldrich
(St Louis, MO, USA). Dulbeccos’s modiﬁed Eagle’s medium (DMEM)
and other cell culture reagents including fetal bovine serum (FBS)
were products of Gibco BRL (Grand Island, NY, USA). The protein
assay kit was purchased from Bio-Rad (Hercules, CA, USA). All an-
tibodies relating to mitogen-activated protein kinase (MAPK) and
Janus kinase (JAK)/signal transducer and activator of transcription
(STAT) signaling were purchased from Cell Signaling Technologies
(Dancers, MA, USA). Lamin B1 antibody was purchased from Bio-
world technology (Minneapolis, MN, USA).
2.2. Preparation of ginseng products
Korean Red Ginseng was purchased from a local market (Seoul).
Dried root powder was extracted three times with 70% ethanol by
sonication for 3 h, followed by rotary evaporation at 4C under
reduced pressure (total ethanol extract, 28.1% of raw material). The
extract was suspended in distilled water in a separatory funnel and
partitioned with n-butanol three times. The combined fractions
were evaporated to dryness (n-butanol fraction, total ginsenoside-
enriched fraction, 6.5% of raw material), and the ethanol extract
was loaded onto a Diaion HP-20 (SigmaeAldrich) open column
(100 cm  10 cm; the volume of the column was 7.8 L) andsequentially eluted with a methanol gradient beginning with 100%
water and 30%, 65%, and ﬁnally 80% methanol. The enriched gin-
senoside fractions were obtained from 65% methanol (ginsenoside
triol-type-enriched fraction, GTF, 0.7% of raw material) and 80%
methanol eluate (ginsenoside diol-type-enriched fraction, GDF,
1.3% of raw material).
In a separate experiment to obtain ginsenoside diol-type-/F4-
enriched fraction (GDF/F4), the dried ginseng leaves were extracted
with 95% ethanol (total ethanol extract, 22.1% of raw material), and
the extract was dried using a rotary evaporator. The dried extract
was partitioned in distilled water and n-butanol three times
(n-butanol fraction, total ginsenoside-enriched fraction, 5.7% of raw
material). The n-butanol fraction was concentrated for column
chromatography. The n-butanol fraction was adsorbed to Diaion
HP-20 resin (SigmaeAldrich), and was washed with water. Then,
the column was eluted with 100% MeOH. The 100% MeOH fraction
was concentrated to obtain a highly-enriched saponin fraction. To
the fraction, two volumes of double concentrated vinegar (Ottugi,
pH 2.3, acidity 13e14%) were added and then exposed for 30 min at
an oscillation frequency of 2,450 MHz, with a microwave output
power of 700 W (Samsung electronics, RE-C20DB, Seoul, Korea).
The sample used for the experiment (GDF/F4) was ﬁnally obtained
by passing the HP-20 resin eluted with 87% MeOH after washing
with 73% MeOH (87% MeOH fraction, ginsenoside diol-type-/F4-
enriched fraction, 0.4% of raw material). It is mainly composed of
ginsenosides Rd, F4, Rg6, Rg3, Rg5, and Rk1. The composition of
various ginsenosides in each product was examined by high per-
formance liquid chromatography analysis, and the proﬁles are
shown in Fig. 1.
2.3. Animals
Male New Zealand white rabbits (age 5 weeks) were purchased
from Central Experimental Animal Co. (Seoul, Korea). The animals
were maintained in the animal facility (KNU) at 20e22oC under
40e60% relative humidity and a 12-h/12-h (light/dark) cycle. The
Fig. 2. Cytotoxicity of various preparations from Korean Red Ginseng on interleukin
(IL)-1b-treated SW1353 cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide bioassay was carried out to measure the cytotoxicity as described in the
experimental section. All data are represented as arithmetic mean  standard devia-
tion (n ¼ 3). *p < 0.05, signiﬁcantly different from the interleukin-1b-treated control
group. BuOH, n-butanol fraction; Ext, total ethanol extract; GDF, ginsenoside diol type-
enriched fraction; GDF/F4, ginsenoside diol type-/F4-enriched fraction; GTF, ginseno-
side triol-type-enriched fraction.
J.H. Lee et al / MMP-13 downregulation of KRG 57experimental design using the animals was approved by the local
committee for animal experimentation of Kangwon National Uni-
versity (KIACUC-12-0012). The animals were handled according to
the guidelines described in the Food and Drug Administration
(Korea) Guide for the Care and Use of Laboratory Animals
throughout the experiments.
2.4. SW1353 cell culture and MMP-13 induction
SW1353 cells (human chondrosarcoma cell line) purchased
from the American type culture collection (Manassas, VA, USA)
were cultured and treated with IL-1b according to previously
described procedures [12]. In brief, the cells were maintained in
DMEM with 10% FBS, glutamine, and penicillin/streptomycin. To
induce MMP-13, IL-1b (10 ng/mL) with/without test compounds
was added to the cells in serum-free DMEM for 24 h. MMP-13
released in the media was examined by Western blotting analysis
using anti-MMP-13 antibody. All test compounds were initially
dissolved in dimethyl sulfoxide (DMSO) and diluted with serum-
free DMEM to adjust the ﬁnal DMSO concentration to 0.1% (v/v).
Cell viability was checked using MTT bioassay [13]. No effect on cell
viability or the MMP-13 expression level was observed by the
treatment of 0.1% DMSO.
2.5. Cellular mechanisms of inhibition of MMP-13 induction
Using total cellular lysate, expression and phosphorylation of
MAPKs and STAT-1/-2 were examined. Total cellular protein was
extracted with Pro-Prep solution (iNtRON Biotechnology, Kyungki-
Do, Korea) containing 1mM phenylmethylsulfonyl ﬂuoride (PMSF),
1mM sodium orthovanadate, and 1mM sodium ﬂuoride. Expres-
sion of nuclear transcription factor-kB (NF-kB) p65, c-Jun, and c-Fos
was identiﬁed in nuclear fractions. For an extraction of nuclear
proteins, cells were resuspended in 400 mL of buffer A (10mM
HEPES, pH 7.9, 10mM KCl, 0.1mM EDTA, 1mM DTT, 0.5mM PMSF,
1 mg/mL aprotinin, and 1 mg/mL leupeptin) and incubated on ice for
10 min. After 25 mL of 10% NP-40 was added, cells were vortexed for
10 sec and centrifuged at 2,500 g for 2 min. The nuclear pellet was
vigorously vortexed in buffer B (20mM HEPES, pH 7.9, 0.4M NaCl,
1mM EDTA, 1mM DTT, 1mM PMSF, 1 mg/mL aprotinin, and 1 mg/mL
leupeptin) and centrifuged at 16,000 g for 10 min. BCA protein
assay (Pierce, IL, USA) was used to determine protein concentration
in the nuclear fraction. Proteins were separated, blotted, and
visualized as described above.
2.6. Effects of GDF/F4 on GAG release from rabbit cartilage culture
According to the previously described procedures [12], articular
cartilages were excised from the femoral condyles of rabbit knee
and incubated in DMEM containing 5% FBS for 1e2 days. In addi-
tion, approximately 30 mg cartilage fragments per well were
incubated in DMEM containing 1% FBS in 400 mL/well. Cartilages
were treated with 10 ng/mL of human IL-1a (SigmaeAldrich) in the
presence or absence of test compounds for 3 days. The amounts of
released GAG in the supernatant were measured with a Blyscan
sulfated GAG assay kit (Biocolor, Carrickfergus, County Antrim, UK)
based on dimethylmethylene blue assay, according to the manu-
facturer’s protocol.
2.7. Statistical analysis
Experimental values are represented as arithmetic
mean standard deviation. Statistical analysis was evaluated using
one-way analysis of variance followed by Dunnett’s analysis (IBMSPSS Statistics, Version 21, IBM Korea). A p < 0.05 was considered
signiﬁcantly different.
3. Results
3.1. Effects of ginseng preparations on MMP-13 expression
Initially, the cytotoxic effects of total red ginseng ethanol extract,
n-butanol fraction (total ginsenoside-enriched fraction), GDF, GTF,
and GDF/F4 were examined. As shown in Fig. 2, MTT assay demon-
strated that the total extract and GTF did not show signiﬁcant
reduction of cell viability at the tested concentrations when incu-
bated in SW1353 chondrocytes. However, 50 mg/mL of n-butanol
fraction reduced viability (7.0%), and 200 mg/mL of GDF slightly
reduced viability (5.1%), but the results are not statistically signiﬁ-
cant. GDF/F4 showed cytotoxicity at 30 mg/mL (53.0%). Therefore, all
other experiments of n-butanol fraction, GDF, and GDF/F4 fractions
were carried out at lower concentrations than indicated.
When theMMP-13 downregulatory effects of these preparations
were compared in SW1353 cells, the crude extract (up to300 mg/mL)
and GTF (up to 200 mg/mL) failed to downregulate MMP-13
expression (Fig. 3A and 3B). By contrast, the n-butanol fraction
(30 mg/mL) showed signiﬁcant inhibition of MMP-13 expression
(Fig. 3C). In particular, GDF and GDF/F4 showed clear inhibition at
10e100 mg/mL and 5e20 mg/mL, respectively, without cytotoxic ef-
fects (Fig. 3D and 3E). Dexamethasone (10mM) used as a reference
agent strongly inhibited MMP-13 expression as expected. These
results indicate that n-butanol fraction, GDF, and GDF/F4 possess
MMP-13 downregulatory activity, with GDF/F4 having the strongest
inhibition of MMP-13 induction among the preparations tested.
3.2. Cellular inhibitory action mechanisms of GDF/F4 on MMP-13
down-regulation
Next, the cellular mechanisms of MMP-13 downregulation by
GDF/F4, the strongest downregulator, were examined. In SW1353
cells, IL-1b treatment induced MMP-13 expression. Previously, this
induction in IL-1b-treated SW1353 cells was found to be mediated,
at least in part, via activation of transcription factors, such as NF-kB,
activator protein-1 (AP-1), and STAT-1/2 [12,14]. Among upstream
kinases, p38 MAPK and JAK activation were importantly involved
[12]. When the effects on MAPK pathways were examined, GDF/F4
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Fig. 3. Effects of various preparations from Korean Red Ginseng on matrix metalloproteinase-13 expression in interleukin (IL)-1b-treated SW1353 cells. Western blotting analysis
was used to examine the expression levels of matrix metalloproteinase (MMP)-13. Dexamethasone was treated at 10mM. (A) Effect of total ethanol extract (300 mg/mL) on MMP-13
expression (B) Effect of GTF (200 mg/mL) on MMP-13 expression (C) Effect of n-butanol fraction (5, 10, 20 and 30 mg/mL) on MMP-13 expression (D) Effect of GDF (10, 50 and 100 mg/
mL) on MMP-13 expression (E) Effect of GDF/F4 (5, 10, 15 and 20 mg/mL) on MMP-13 expression. All data are represented as arithmetic mean  standard deviation (n ¼ 3). *p < 0.05,
signiﬁcantly different from the interleukin-1b-treated control group. BuOH, n-butanol fraction; Dex, dexamethasone; Ext, total ethanol extract; GDF, ginsenoside diol type-enriched
fraction; GDF/F4, ginsenoside diol type-/F4-enriched fraction; GTF, ginsenoside triol-type-enriched fraction.
J Ginseng Res 2015;39:54e6058inhibited the activation of p38 MAPK and JNK at 20 mg/mL. Among
the transcription factors, the activation of STAT-1/2 was blocked,
but not that of NF-kB and AP-1 (Fig. 4). Thus, it is suggested that
GDF/F4 downregulates MMP-13 expression by blocking the acti-
vation of multiple points including MAPKs and the transcription
factor, STAT-1/2.3.3. Inhibition of GAG release from rabbit cartilage culture
To establish the cartilage protective effect of the new prepara-
tion, rabbit cartilage tissue culture was employed. IL-1a treatment
of rabbit cartilage induced MMPs, which degraded the matrix
materials and released large amounts of GAG into the media for a
3-day culture (Fig. 5). Under this condition, GDF/F4 inhibited GAG
release (30.6% and 19.3%) from rabbit cartilage at 30mM and 50mM,respectively, whereas the reference compound, diclofenac (30mM),
showed strong inhibition (64.1%) as expected. However, Korean Red
ginseng total ethanol extract did not protect the GAG release at
200 mg/mL under the same experimental conditions.4. Discussion
The present study clearly demonstrates that the ginsenoside-
enriched fraction (n-BuOH fraction) and the newly prepared GDF
and GDF/F4 inhibited MMP-13 expression in human chondrocytes.
However, the red ginseng total extract and GTF did not signiﬁcantly
inhibit MMP-13 induction. In addition, GDF/F4 was also found to
give considerable protection of cartilage degradation in rabbit
cartilage culture, although this was not statistically signiﬁcant.
Fig. 4. Effects of ginsenoside diol type-/F4-enriched fraction (GDF/F4) on the various signal transduction pathways of matrix metalloproteinase-13 expression in interleukin-
1b-treated SW1353 cells. Western blotting analysis was used to examine the expression levels of various signaling molecules. All data are represented as arithmetic
mean  standard deviation (n ¼ 3). *p < 0.05, signiﬁcantly different from the interleukin-1b-treated control group. JNK, c-Jun-activated protein kinase; NF-kB, nuclear factor-kB;
STAT, signal transducer and activator of transcription.
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Fig. 5. Effects of ginsenoside diol type-/F4-enriched fraction (GDF/F4) on glycosami-
noglycan (GAG) release fromrabbit cartilage culture. Rabbit cartilagewas incubatedwith
interleukin (IL)-1a in thepresenceorabsenceof the test samples. All data are represented
as arithmetic mean  standard deviation (n ¼ 4). *p < 0.05, signiﬁcantly different from
the interleukin-1a-treated group. Dic, diclofenac; Ext, total ethanol extract.
J Ginseng Res 2015;39:54e6060Previously, it was found that ginsenosides Rc, Rd, Rf, F4, Rg1, and
Rg3 possess MMP-13 downregulatory activity against IL-1b-treated
chondrocytes at concentrations of 1e50mM [11]. The most promi-
nent inhibitors are ginsenosides Rg3 and F4. In this study, GDF/F4
was newly prepared from Panax ginseng leaves because the leaves
containhigheramountsof F4andRg3 thanginseng rootsonaweight
basis. However, the total ginseng extract (the ethanol extract) did
not exert MMP-13 downregulation. The inactive result of the total
extract is possibly explained by the fact that the contents of these
active ginsenosides in the extractmight be too low to exertMMP-13
downregulation, as shown in Fig. 2. Otherwise, it is reasonable to
think that if these active ginsenosides are enriched in certain frac-
tions, theymay possess meaningful inhibitory action. Indeed, the n-
BuOH fraction (total ginsenoside-enriched fraction, Fig. 2) having
higher amounts of ginsenosides strongly inhibited MMP-13 induc-
tion. In this case, however, some cytotoxicity was observed on
SW1353 cells at the concentrations of 50 mg/mL or higher. The
cytotoxic property of the n-butanol fraction could be, at least partly,
explained by the previous ﬁndings that ginsenosides such as Rg3,
Rg5, and Rk1 exert considerable cytotoxicity on SW1353 cells and
several other cells at high concentrations [7,11,15].
Because the major active ginsenosides are diol-type and F4 [11],
we designed a new preparation that contains high amounts of the
diol-type ginsenosides and F4, i.e., GDF/F4. As expected, the most
prominent active preparations forMMP-13downregulation areGDF
and GDF/F4, with GDF/F4 being the strongest. It is understood that
theMMP-13downregulatoryactionof thesepreparationsmight rely
on the major ginsenosides of GDF (Rc and Rd) and GDF/F4 (Rc, Rd,
Rg3, and F4). By contrast, the ginsenoside triol-type-enriched frac-
tion (GTF) did not inhibit MMP-13 expression. Actually, among
ginsenoside triol-type derivatives, Rf and Rg1 were found to inhibit
MMP-13 expression weakly at high concentrations [11].
It was previously found that MAPKs, NF-kB, AP-1, and STAT-1/-2
are important to induce MMP-13 in IL-1b-treated SW1353 cells
[12,14]. GDF/F4 blocked the activation of MAPKs, including p38
MAPK and JNK and transcription factors STAT-1/2. However, one
prominent MMP-13 downregulating ginsenoside, F4, was previ-
ously found to block only p38 MAPK activation under the same
experimental conditions [11]. These differences may be because
GDF/F4 contains several different ginsenosides in addition to F4.
It is important to indicate that most active MMP-13 down-
regulating ginsenosides are the components of Korean Red
Ginseng, but not of white ginseng [8,9]. Rg3 and F4 are unique to
Korean Red Ginseng. These results may suggest the importance of
Korean Red Ginseng for treating cartilage degradation disorders.In conclusion, some ginsenoside-enriched fractions (n-BuOH
fraction, GDF, and GDF/F4) were, for the ﬁrst time, found to inhibit
MMP-13 expression from chondrocytes, at least in part, via blocking
the activation of p38MAPK, JNK, and STAT-1/2. GDF/F4 also showed
some protective activity against cartilage degradation in rabbit
cartilage tissue culture. Our study may open a new therapeutic area
for red ginseng product(s). These products may be beneﬁcial for
chondroprotection in cartilage degradation-related disorders such
as osteoarthritis.
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